New HPV vaccine batch trial aims to ensure reliable protection
NCT ID NCT07668271
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial is testing whether three different batches of a 9-valent HPV vaccine produce similar immune responses in 720 women aged 18-30 in China. Participants will receive three doses over six months, and researchers will measure antibody levels one month after the final dose. The goal is to ensure consistent quality for international approval.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 9-valent HPV vaccine (Cecolin 9)
- What this could lead to
- If successful, this could confirm that the vaccine works consistently across batches, supporting its use in preventing HPV infections and related cancers.
- What could go wrong
- This is a late-stage consistency trial, not a test of effectiveness. It may not show how well the vaccine prevents disease in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFECTION BY HUMAN PAPILLOMA VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhangping Center for Disease Control and Prevention
RECRUITINGZhangping, Fujian, 364400, China